 |
|
|
| |
INTEGRATED EFFICACY ANALYSIS OF FOUR PHASE 3 STUDIES IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 9
Gregory T. Everson, Geoffrey Dusheiko, Eoin Coakley, Stephen Shafran, Fabien Zoulim, Moisés Diago, Ravi Ravinuthala, Suzanne Norris, Bo Fu, Roger Trinh, Yan Luo, Thomas Podsadecki, Mark S. Sulkowski
|
| |
|
|
|
|
|
